Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 330

Similar articles for PubMed (Select 18711155)

1.

The ADVANTAGE seeding trial: a review of internal documents.

Hill KP, Ross JS, Egilman DS, Krumholz HM.

Ann Intern Med. 2008 Aug 19;149(4):251-8. Review.

PMID:
18711155
2.

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.

Ross JS, Hill KP, Egilman DS, Krumholz HM.

JAMA. 2008 Apr 16;299(15):1800-12. doi: 10.1001/jama.299.15.1800.

PMID:
18413874
3.
4.

Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial.

Krumholz SD, Egilman DS, Ross JS.

Arch Intern Med. 2011 Jun 27;171(12):1100-7. doi: 10.1001/archinternmed.2011.241.

5.

Clinical trials and tribulations. Allegations of waste: the 'seeding' study.

Malakoff D.

Science. 2008 Oct 10;322(5899):213. doi: 10.1126/science.322.5899.213. No abstract available.

PMID:
18845743
6.

Vioxx doctors wooed by Merck are now its foes.

Tesoriero HW.

Wall St J (East Ed). 2006 Mar 10:B1, B3. No abstract available.

PMID:
16578911
7.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
8.

The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.

Cahana A, Mauron A.

J Anesth. 2006;20(4):348-51. No abstract available.

PMID:
17072707
9.

Conflicts of interest in drug development: the practices of Merck & Co., Inc.

Hirsch LJ.

Sci Eng Ethics. 2002 Jul;8(3):429-42. Review.

PMID:
12353373
10.

Seeding trials: just say "no".

Sox HC, Rennie D.

Ann Intern Med. 2008 Aug 19;149(4):279-80. No abstract available. Erratum in: Ann Intern Med. 2008 Sep 16;149(6):439.

PMID:
18711161
11.

[Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx) in Germany between 2001 and 2004].

Sawicki PT, Bender R, Selke GW, Klauber J, Gutschmidt S.

Med Klin (Munich). 2006 Mar 15;101(3):191-7. German.

PMID:
16648975
12.

ADVANTAGE: Merck does say "no".

Rabin A.

Ann Intern Med. 2008 Nov 18;149(10):774. No abstract available.

PMID:
19017608
13.

ADVANTAGE: Merck does say "no".

Edelman JM.

Ann Intern Med. 2008 Nov 18;149(10):774-5; author reply 775. No abstract available.

PMID:
19017607
14.

Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation.

Graham DY, Jewell NP, Chan FK.

Am J Med Sci. 2011 Nov;342(5):356-64. doi: 10.1097/MAJ.0b013e3182113658.

16.

Merck's actions surrounding Vioxx.

Heinley M.

PLoS Med. 2006 Jun;3(6):e286; author reply e285. Epub 2006 Jun 27. No abstract available.

18.

Narrative review: the promotion of gabapentin: an analysis of internal industry documents.

Steinman MA, Bero LA, Chren MM, Landefeld CS.

Ann Intern Med. 2006 Aug 15;145(4):284-93. Review.

PMID:
16908919
19.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. German.

PMID:
19034813
20.

ADVANTAGE: science first, marketing second.

Edelman JM.

Ann Intern Med. 2008 Nov 18;149(10):773; author reply 773-4. No abstract available.

PMID:
19017606
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk